8-K: Cadrenal Raises $2.2M via Stock and Warrants Offering

Cadrenal Therapeutics, Inc. announced a registered direct offering and concurrent private placement to raise approximately $2.2 million for working capital.

Summary

• Cadrenal Therapeutics, Inc. entered into a securities purchase agreement on December 15, 2025, for a registered direct offering and concurrent private placement.
• The registered direct offering involves the sale of 207,374 shares of common stock at an offering price of $10.85 per share.
• The concurrent private placement includes unregistered warrants (Common Warrants) to purchase up to 414,748 shares of common stock, exercisable at $10.60 per share.
• The company expects to receive gross proceeds of approximately $2.2 million from the offering.
• The offering is anticipated to close on or about December 16, 2025, subject to customary closing conditions.
• Directors and officers of the company have entered into 10-day lock-up agreements following the closing date.
• The company has agreed to certain restrictions on future equity issuances for 10 days post-closing and on Variable Rate Transactions for one year, with an exception for at-the-market sales with H.C. Wainwright & Co., LLC after 10 days.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee, a 1% management fee, $10,000 for non-accountable expenses, and $10,000 for clearing fees.
• The placement agent will also receive warrants (Placement Agent Warrants) to purchase up to 13,479 shares of common stock, exercisable at $13.5625 per share (125% of the offering price).
• The company will file a registration statement for the resale of the Common Warrant Shares within 30 calendar days and aims for it to be effective within 60-90 calendar days.

Sentiment

Score: 5

Explanation: The offering provides necessary capital for working capital, which is a positive for operations. However, it comes with significant dilution for existing shareholders and substantial fees to the placement agent, balancing the overall sentiment to neutral.

Positives

• Successfully secured approximately $2.2 million in gross proceeds, providing capital for working capital purposes.
• The company affirmed its solvency and ability to meet existing debts and liabilities after the offering.
• The offering includes a registered direct component, indicating a degree of market access and investor interest.

Negatives

• The offering involves significant dilution for existing shareholders due to the issuance of new common stock and warrants.
• Substantial fees and expenses are associated with the offering, including an 8% cash fee (7% placement agent fee + 1% management fee) plus additional expenses and warrants to the placement agent.
• The exercise price of the Common Warrants ($10.60) is below the offering price of the shares ($10.85), potentially indicating a discount to attract investors.

Risks

• Dilution of outstanding shares of common stock, which may be substantial under certain market conditions, is explicitly acknowledged.
• Market price of the company's publicly-traded securities may be negatively impacted by past or future open market or derivative transactions by purchasers, including Short Sales or hedging activities.
• Restrictions on resale of unregistered Common Warrants and Common Warrant Shares, requiring an effective registration statement or Rule 144 eligibility for transfer.
• Potential for liquidated damages if the company fails to timely deliver unlegended shares or maintain current public information under Rule 144.

Future Outlook

The company intends to use the net proceeds from the offering for working capital purposes. It has committed to filing a registration statement for the resale of the Common Warrant Shares within 30 calendar days and will use commercially reasonable efforts to have it declared effective within 60 to 90 calendar days.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and warrants, potentially impacting per-share value.
• Investors in the offering: Will acquire common stock and warrants, providing them with equity exposure and potential upside through warrant exercise.
• Placement Agent (H.C. Wainwright & Co., LLC): Will receive substantial cash fees and warrants for facilitating the capital raise.
• Employees: No direct impact mentioned, but the capital raise for working capital could support ongoing operations and job security.

Next Steps

• Closing of the registered direct offering and concurrent private placement on or about December 16, 2025.
• Filing of a registration statement to register the resale of the Common Warrant Shares within 30 calendar days of the Purchase Agreement date.
• Using commercially reasonable efforts to have the resale registration statement declared effective by the SEC within 60 calendar days (or 90 days if subject to full review).

Key Dates

Recommendation

The capital raise provides essential working capital, which is a positive for the company's operational continuity. However, the significant dilution from the new shares and warrants, coupled with the associated fees, offsets much of this benefit for existing shareholders. Without further information on the company's specific pipeline or operational advancements, the offering primarily serves as a necessary financing step rather than a catalyst for strong growth, suggesting a 'hold' position for investors to monitor future developments.

Keywords

Cadrenal Therapeutics, CVKD, SEC filing, 8-K, equity offering, private placement, common stock, warrants, capital raise, dilution, financial reporting, Nasdaq, biotechnology, pharmaceutical